Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 10/20 | 0.48 |
| ▸ | AXL | P30530 | 6/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13955463 | 0.95 | PDGFRA (0.49) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL13955465 | 0.91 | FGFR2 (0.58) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL12499486 | 0.85 | FGFR2 (0.56) | FGFR2PDGFRAMETKDRPDGFRB | |
| SCHEMBL13787639 | 0.85 | SRC (0.61) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL4575949 | 0.84 | AXL (0.57) | FGFR2PDGFRAMETAXLKDR | |
| Bromide SCHEMBL15918462 | 0.83 | AXL (0.56) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL4575945 | 0.82 | MET (0.52) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL19372993 | 0.82 | FGFR2 (0.62) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL22521192 | 0.81 | FGFR2 (0.59) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL165288 | 0.81 | PDGFRA (0.52) | FGFR2PDGFRAMETAXLKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184523-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | FGFR2 529/4885PDGFRA 182/4885MET 2/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | FGFR2 36/4885PDGFRA 26/4885MET 3/4885 |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | FLT3, TYRO3, ABL1 | FGFR2 1020/4885PDGFRA 229/4885MET 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.